These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12041771)

  • 1. Efficacy and safety of teicoplanin in gram-positive pulmonary infections.
    Sanduzzi A; Nani E; Sarno M; Vatrella A; Parrella R; Mattiello A
    J Chemother; 1991 Jan; 3 Suppl 1():224-6. PubMed ID: 12041771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
    Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
    J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of teicoplanin in the ambulatory treatment of infections in children due to gram-positive microorganisms].
    Debbag R; Paganini H; Gómez S; Casimir L; Stamboulian D
    Medicina (B Aires); 2002; 62 Suppl 2():48-51. PubMed ID: 12481489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The use of teicoplanin for Gram-positive infections in patients with kidney transplantation].
    Jákics J; Gálffy Z; Hernold L; Rácz A; Perner F
    Orv Hetil; 1996 Jun; 137(25):1355-8. PubMed ID: 8757082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbiological profile of teicoplanin.
    Covelli I; Nani E
    J Chemother; 1991 Jan; 3 Suppl 1():39-42. PubMed ID: 12041783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients.
    Wilson AP; Cepeda JA; Hayman S; Whitehouse T; Singer M; Bellingan G
    J Antimicrob Chemother; 2006 Aug; 58(2):470-3. PubMed ID: 16735420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Teicoplanin and Gram-positive coccus infections. Results of a multicenter study on 66 cases].
    Dureux JB; Canton P; Chavanet P; Chippaux C; Dupeyron JP; Estavoyer JM; Giorgi C; Jaeger A; Jehl F; Kazmierzack A
    Pathol Biol (Paris); 1987 May; 35(5):511-5. PubMed ID: 2956564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Microbiological-clinical study on the efficacy of a new antibiotic: teicoplanin].
    Martinetto P; Gariglio M; Malcangi A; Cavallo GP
    G Batteriol Virol Immunol; 1985; 78(1-6):86-94. PubMed ID: 2943627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.
    Wilcox M; Nathwani D; Dryden M
    J Antimicrob Chemother; 2004 Feb; 53(2):335-44. PubMed ID: 14729745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The first clinical experiences in Hungary with a new effective antibiotic (linezolid) effective against Gram-positive infections].
    Pulay I; Konkoly TM; Zsirka KA; Csapó Z; Flautner L; Tihanyi T
    Orv Hetil; 2003 Jan; 144(1):29-33. PubMed ID: 12635350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of serious gram-positive infections with teicoplanin.
    Davies AJ; Stone JM; Synott M
    Drugs Exp Clin Res; 1989; 15(1):29-31. PubMed ID: 2526010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teicoplanin for therapy of gram-positive infections in neutropenic patients.
    Verhagen C; De Pauw BE
    Int J Clin Pharmacol Res; 1987; 7(6):491-8. PubMed ID: 2964418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of efficacy and safety of teicoplanin in gram-positive infections: a multicentre study.
    Lang E; Schäfer V; Schaaf B; Dennhardt R
    Scand J Infect Dis Suppl; 1990; 72():54-60. PubMed ID: 2151067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of teicoplanin as antimicrobial treatment of severe nosocomial infections caused by gram-positive bacteria: a preliminary study.
    Micozzi A; Venditti M; Brandimarte C; Baiocchi P; Martino P; Serra P
    Chemioterapia; 1988 Apr; 7(2):101-4. PubMed ID: 2969302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open evaluation of the efficacy and safety of the new macrolide roxithromycin in the treatment of lower respiratory tract infections and pneumonia in Nigerian patients.
    Isah AO; Ohaju-Obodo J
    West Afr J Med; 1996; 15(2):111-6. PubMed ID: 8855675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
    Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
    Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current treatment of gram-positive infections: focus on efficacy, safety, and cost minimalization analysis of teicoplanin.
    Crane VS; Garabedian-Ruffalo SM
    Hosp Formul; 1992 Dec; 27(12):1199-200, 1203-4, 1207-10. PubMed ID: 10122506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of teicoplanin in 25 cases of severe infections caused by gram-positive cocci].
    Potel G; Touzé MD; Meignier M; Reynaud A; Baron D
    Pathol Biol (Paris); 1988 May; 36(5):531-5. PubMed ID: 2970058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.